Close Menu

ORLANDO, Florida (GenomeWeb) – Early-access customers of NanoString's Hyb & Seq sequencing technology and its Digital Spatial Profiling technologies described how they are using the technologies in cancer and infectious disease at the Advances in Genome Biology and Technology meeting held here this week. 

As previously announced, NanoString plans to launch its DSP technology in early access in the second half of the year with full commercial launch in 2019, and it is targeting 2019 for an early-access launch of its Hyb & Seq platform.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Mauro Ferrari has resigned as president of the European Research Council over its response to the COVID-19 pandemic, the Financial Times reports.

Researchers in India plan to sequence SARS-CoV-2 isolates from around the country, according to LiveMint.

Stat News reports some health tech startups are laying off or furloughing workers.

In Genome Research this week: indels affecting microsatellites in cancer, analytical approach to find key regulatory elements, and more.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.

May
19
Sponsored by
10x Genomics

Uveal melanoma (UM) is a highly metastatic cancer that, in contrast to cutaneous melanoma, is largely unresponsive to checkpoint immunotherapy.